Evidence map›Paper›PMID 38296221›Full record

ArticleAnnals of hepato-biliary-pancreatic surgery2024

Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer.

Evelyn Waugh, Juan Glinka, Daniel Breadner, Rachel Liu, Ephraim Tang, Laura Allen, Stephen Welch, Ken Leslie, Anton Skaro

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hepato-biliary-pancreatic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Evelyn WaughDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0002-1720-7281
Juan GlinkaDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0003-4373-965X
Daniel BreadnerDivision of Medical Oncology, Department of Oncology, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0001-5379-7621
Rachel LiuDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0003-0699-8361
Ephraim TangDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0002-2392-3380
Laura AllenDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0002-8169-9567
Stephen WelchDivision of Medical Oncology, Department of Oncology, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0003-1455-4664
Ken LeslieDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0009-0003-7917-060X
Anton SkaroDivision of General Surgery, Department of Surgery, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0002-9215-647X
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds/Aims: While patients with borderline resectable pancreatic cancer (BRPC) are a target population for neoadjuvant chemotherapy (NAC), formal guidelines for neoadjuvant therapy are lacking. We assessed the perioperative and oncological outcomes in patients with BRPC undergoing NAC with FOLFIRINOX for patients undergoing upfront surgery (US). Methods: The AHPBA criteria for borderline resectability and/or a CA19-9 level > 100 μ/mL defined borderline resectable tumors retrieved from a prospectively populated institutional registry from 2007 to 2020. The primary outcome was overall survival (OS) at 1 and 3 years. A Cox Proportional Hazard model based on intention to treat was used. A receiver-operator characteristics (ROC) curve was constructed to assess the discriminatory capability of the use of CA19-9 > 100 μ/mL to predict resectability and mortality. Results: Forty BRPC patients underwent NAC, while 46 underwent US. The median OS with NAC was 19.8 months (interquartile range [IQR], 10.3-44.24) vs. 10.6 months (IQR, 6.37-17.6) with US. At 1 year, 70% of the NAC group and 41.3% of the US group survived ( Conclusions: We found a survival benefit of NAC with FOLFIRINOX for BRPC. Greater pre-treatment of CA19-9 and multivessel involvement on initial imaging were associated with progression of the disease following NAC.

Indexed as

CA-19-9 antigenNeoadjuvant therapyPancreatic cancerPancreatic neoplasms

Identifiers

PMID38296221
PMCPMC11128787
OpenAlexW4391917303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.